替罗非班治疗缺血性脑血管病的效果分析

Effect analysis of tirofiban on ischemic cerebrovascular disease

目的 分析缺血性脑血管病患者采用替罗非班治疗的临床效果。方法 100例缺血性脑血管病患者,采用随机数字表法分为对照组和观察组,每组50例。对照组患者选择常规溶栓治疗,观察组患者在对照组基础上采用替罗非班治疗。对比两组患者临床疗效、不良反应发生率、生活质量、神经功能。结果 治疗后72 h,观察组患者和对照组患者病情进展率对比未表现出明显差异(P>0.05);治疗后1周,观察组患者病情进展率4.00%明显低于对照组的18.00%(P<0.05)。随访1周后,观察组患者不良反应发生率8.00%明显低于对照组的24.00%(P<0.05)。两组患者治疗前社会功能、心理功能、躯体功能评分对比未表现出明显差异(P>0.05);观察组患者治疗后社会功能、心理功能、躯体功能评分分别为(80.56±7.22)、(74.30±7.13)、(77.26±7.35)分,明显高于对照组的(60.71±8.28)、(63.51±6.05)、(64.45±7.26)分(P<0.05)。两组患者治疗前美国国立卫生研究院卒中量表(NIHSS)评分对比未表现出明显差异(P>0.05);治疗后72 h及1周,观察组患者NIHSS评分分别为(4.18±1.45)、(3.60±1.05)分,均低于对照组的(8.26±1.84)、(6.42±1.71)分(P<0.05)。结论 缺血性脑血管病患者采用替罗非班治疗,能够稳定病情,降低不良反应发生率,提高患者治疗期间的生活质量,大幅度改善患者神经功能。

Objective To analyze the clinical effect of tirofiban on ischemic cerebrovascular disease.Methods 100 patients with ischemic cerebrovascular disease were divided into a control group and an observation group by random number table method,with 50 cases in each group.The control group was treated with conventional thrombolytic therapy,and the observation group was treated with tirofiban on the basis of the control group.The clinical efficacy,incidence of adverse reactions,quality of life and neurological function were compared between the two groups.Results At 72 h after treatment,there was no significant difference in rate of disease progression between the observation group and the control group(P>0.05).At 1 week after treatment,the rate of disease progression of 4.00%in the observation group was significantly lower than 18.00%in the control group(P<0.05).After 1 week of follow-up,the incidence of adverse reactions of 8.00%in the observation group was significantly lower than 24.00%in the control group(P<0.05).Before treatment,there were no significant differences in the scores of social function,psychological function and physical function between the two groups(P>0.05).After treatment,the scores of social function,psychological function and physical function in the observation group were(80.56±7.22),(74.30±7.13)and(77.26±7.35)points,which were significantly higher than(60.71±8.28),(63.51±6.05)and(64.45±7.26)points in the control group(P<0.05).Before treatment,there was no significant difference in the National Institutes of Health Stroke Scale(NIHSS)score between the two groups(P>0.05).At 72 h and 1 week after treatment,the NIHSS scores of the observation group were(4.18±1.45)and(3.60±1.05)points,which were lower than(8.26±1.84)and(6.42±1.71)points of the control group(P<0.05).Conclusion Tirofiban treatment in patients with ischemic cerebrovascular disease can stabilize the condition,reduce the incidence of adverse reactions,improve the quality of life of patients during treatment,and greatly improve the neurological function of patients.